Shine-On BioMedical Co.,Ltd.
Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody. Shine-On BioMedical Co.,Ltd… Read more
Shine-On BioMedical Co.,Ltd. (6926) - Net Assets
Latest net assets as of June 2025: NT$972.93 Million TWD
Based on the latest financial reports, Shine-On BioMedical Co.,Ltd. (6926) has net assets worth NT$972.93 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$982.08 Million) and total liabilities (NT$9.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$972.93 Million |
| % of Total Assets | 99.07% |
| Annual Growth Rate | 3.89% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 17.29 |
Shine-On BioMedical Co.,Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how Shine-On BioMedical Co.,Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shine-On BioMedical Co.,Ltd. (2021–2024)
The table below shows the annual net assets of Shine-On BioMedical Co.,Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.02 Billion | -10.46% |
| 2023-12-31 | NT$1.14 Billion | -3.17% |
| 2022-12-31 | NT$1.17 Billion | +29.32% |
| 2021-12-31 | NT$907.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shine-On BioMedical Co.,Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17560200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$498.00 Million | 48.94% |
| Other Components | NT$703.60 Million | 69.15% |
| Total Equity | NT$1.02 Billion | 100.00% |
Shine-On BioMedical Co.,Ltd. Competitors by Market Cap
The table below lists competitors of Shine-On BioMedical Co.,Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IMMUCELL CORP. DL-10
F:IUL
|
$33.28 Million |
|
Coreline Soft, Co., Ltd.
KQ:384470
|
$33.29 Million |
|
Scottie Resources Corp
OTCQB:SCTSF
|
$33.31 Million |
|
Swelect Energy Systems Limited
NSE:SWELECTES
|
$33.33 Million |
|
Hsin Ba Ba Corp
TW:9906
|
$33.28 Million |
|
Gala Precision Engineering
NSE:GALAPREC
|
$33.28 Million |
|
Boab Metals Limited
PINK:PMYLF
|
$33.27 Million |
|
Waga Energy SA
PA:WAGA
|
$33.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shine-On BioMedical Co.,Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,136,460,000 to 1,017,567,000, a change of -118,893,000 (-10.5%).
- Net loss of 118,893,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-118.89 Million | -11.68% |
| Total Change | NT$- | -10.46% |
Book Value vs Market Value Analysis
This analysis compares Shine-On BioMedical Co.,Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.24x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$19.99 | NT$66.30 | x |
| 2022-12-31 | NT$25.85 | NT$66.30 | x |
| 2023-12-31 | NT$22.82 | NT$66.30 | x |
| 2024-12-31 | NT$20.43 | NT$66.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shine-On BioMedical Co.,Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-11.68%) is below the historical average (-4.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -0.93% | 0.00% | 0.00x | 1.00x | NT$-99.19 Million |
| 2022 | -1.67% | 0.00% | 0.00x | 1.00x | NT$-136.91 Million |
| 2023 | -3.27% | -390.22% | 0.01x | 1.02x | NT$-150.81 Million |
| 2024 | -11.68% | 0.00% | 0.00x | 1.04x | NT$-220.65 Million |
Industry Comparison
This section compares Shine-On BioMedical Co.,Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shine-On BioMedical Co.,Ltd. (6926) | NT$972.93 Million | -0.93% | 0.01x | $33.28 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |